Our findings suggest that further investigation of the lipid pathway in BMs of EGFR-mutant lung cancer patients is warranted and that lipid metabolism may be the next potential preventive therapeutic target for LUAD BM. This evidence concerns the gene EGFR and lung carcinoma.